Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. 2009

Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
Genentech, Inc., South San Francisco, California, USA. polson@gene.com

Antibody-drug conjugates (ADC), potent cytotoxic drugs covalently linked to antibodies via chemical linkers, provide a means to increase the effectiveness of chemotherapy by targeting the drug to neoplastic cells while reducing side effects. Here, we systematically examine the potential targets and linker-drug combinations that could provide an optimal ADC for the treatment for non-Hodgkin's lymphoma. We identified seven antigens (CD19, CD20, CD21, CD22, CD72, CD79b, and CD180) for potential treatment of non-Hodgkin's lymphoma with ADCs. ADCs with cleavable linkers mediated in vivo efficacy via all these targets; ADCs with uncleavable linkers were only effective when targeted to CD22 and CD79b. In target-independent safety studies in rats, the uncleavable linker ADCs showed reduced toxicity, presumably due to the reduced release of free drug or other toxic metabolites into the circulation. Thus, our data suggest that ADCs with cleavable linkers work on a broad range of targets, and for specific targets, ADCs with uncleavable linkers provide a promising opportunity to improve the therapeutic window for ADCs in humans.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008453 Maytansine An ansa macrolide isolated from the MAYTENUS genus of East African shrubs. Maitansine,DMMO-Maytansine,Emtansine,Maytansinoid DM1,Maytansinoid DM4,Mertansine,N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine,Ravtansine,Soravtansine,DM1, Maytansinoid,DM4, Maytansinoid,DMMO Maytansine
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D003432 Cross-Linking Reagents Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. Bifunctional Reagent,Bifunctional Reagents,Cross Linking Reagent,Crosslinking Reagent,Cross Linking Reagents,Crosslinking Reagents,Linking Reagent, Cross,Linking Reagents, Cross,Reagent, Bifunctional,Reagent, Cross Linking,Reagent, Crosslinking,Reagents, Bifunctional,Reagents, Cross Linking,Reagents, Cross-Linking,Reagents, Crosslinking
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000922 Immunotoxins Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect. Affinotoxin,Antibody-Toxin Conjugate,Antibody-Toxin Conjugates,Antibody-Toxin Hybrid,Antibody-Toxin Hybrids,Chimeric Toxins,Cytotoxin-Antibody Conjugate,Cytotoxin-Antibody Conjugates,Monoclonal Antibody-Toxin Conjugate,Targeted Toxin,Targeted Toxins,Toxin Carriers,Toxin Conjugates,Toxin-Antibody Conjugate,Toxin-Antibody Conjugates,Toxin-Antibody Hybrid,Toxin-Antibody Hybrids,Toxins, Chimeric,Toxins, Targeted,Affinotoxins,Chimeric Toxin,Immunotoxin,Monoclonal Antibody-Toxin Conjugates,Toxin Carrier,Toxin Conjugate,Antibody Toxin Conjugate,Antibody Toxin Conjugates,Antibody Toxin Hybrid,Antibody Toxin Hybrids,Antibody-Toxin Conjugate, Monoclonal,Antibody-Toxin Conjugates, Monoclonal,Carrier, Toxin,Carriers, Toxin,Conjugate, Antibody-Toxin,Conjugate, Cytotoxin-Antibody,Conjugate, Monoclonal Antibody-Toxin,Conjugate, Toxin,Conjugate, Toxin-Antibody,Conjugates, Antibody-Toxin,Conjugates, Cytotoxin-Antibody,Conjugates, Monoclonal Antibody-Toxin,Conjugates, Toxin,Conjugates, Toxin-Antibody,Cytotoxin Antibody Conjugate,Cytotoxin Antibody Conjugates,Hybrid, Antibody-Toxin,Hybrid, Toxin-Antibody,Hybrids, Antibody-Toxin,Hybrids, Toxin-Antibody,Monoclonal Antibody Toxin Conjugate,Monoclonal Antibody Toxin Conjugates,Toxin Antibody Conjugate,Toxin Antibody Conjugates,Toxin Antibody Hybrid,Toxin Antibody Hybrids,Toxin, Chimeric,Toxin, Targeted
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
March 2013, Future oncology (London, England),
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
November 2015, Pharmaceutical research,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
January 2013, Methods in molecular biology (Clifton, N.J.),
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
September 2010, Leukemia,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
March 2015, The AAPS journal,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
June 2024, Analytical methods : advancing methods and applications,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
July 2007, Blood,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
March 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
June 2015, The Lancet. Oncology,
Andrew G Polson, and Jill Calemine-Fenaux, and Pamela Chan, and Wesley Chang, and Erin Christensen, and Suzanna Clark, and Frederic J de Sauvage, and Dan Eaton, and Kristi Elkins, and J Michael Elliott, and Gretchen Frantz, and Reina N Fuji, and Alane Gray, and Kristin Harden, and Gladys S Ingle, and Noelyn M Kljavin, and Hartmut Koeppen, and Christopher Nelson, and Saileta Prabhu, and Helga Raab, and Sarajane Ross, and Dion S Slaga, and Jean-Philippe Stephan, and Suzie J Scales, and Susan D Spencer, and Richard Vandlen, and Bernd Wranik, and Shang-Fan Yu, and Bing Zheng, and Allen Ebens
May 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Copied contents to your clipboard!